← Back to screener

IOVANCE BIOTHERAPEUTICS, INC. IOVA

Rank #2429 · Nasdaq · $3.8B market cap
Audited by Ernst & Young LLP, no going-concern flag in the latest filing.
Score
19.3
P/E
-8.5
P/B
7.58
ROE
-88.9%
Op. Margin
-38735.0%
Debt Ratio
40%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆
Poor

P/E -8.5x, P/B 7.58x. Ranks in the top 80% of the universe.

Profitability ★☆☆☆☆
Poor

ROE -88.9%. Ranks in the top 96% of the universe.

Safety ★★★★☆
Excellent

Debt ratio 40%. Ranks in the top 20% of the universe. Under 100% is generally considered a safe level.

Growth ★★☆☆☆
Weak

Revenue growth of 0.0% year over year. Ranks in the top 64% of the universe.

Safety is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2011–$-0.0B$-0.0B$0.0B––
2012–$-0.0B$-0.0B$0.0B––
2013–$-0.0B$-0.0B$0.0B–268
2014$0.0B$-0.0B$-0.0B$-0.0B–-276
2015$0.0B$-0.0B$-0.0B$-0.0B–-511
2016$0.0B$-0.0B$-0.0B$0.0B–500
2017$0.0B$-0.0B$-0.0B$0.0B–283
2018$0.0B$-0.1B$-0.1B$0.1B–10
2019–$-0.1B$-0.1B$0.2B–9
2020–$-0.1B$-0.1B$0.1B–31
2021–$-0.2B$-0.2B$0.5B–24
2022–$-0.3B$-0.3B$0.3B–52
2023$0.0B$-0.3B$-0.3B$0.7B-28822.825
2024$0.0B$-0.4B$-0.4B$0.6B-33547.431
2025$0.0B$-0.5B$-0.4B$0.5B-38735.040

← See the full screener